カテゴリー： QYResearch, 世界, 医療/バイオ

世界のSERD（選択エストロゲン受容体分解）薬市場インサイト及び予測（RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他）

◆英語タイトル：Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09283 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：111 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、SERD（選択エストロゲン受容体分解）薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にSERD（選択エストロゲン受容体分解）薬の世界市場のxxx％を占める「RAD1901」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「一次治療」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
SERD（選択エストロゲン受容体分解）薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのSERD（選択エストロゲン受容体分解）薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

SERD（選択エストロゲン受容体分解）薬のグローバル主要企業には、Amneal Pharmaceuticals Inc、AstraZeneca, Plc.、Dr. Reddy's Laboratories、Eli Lilly and Company、G1 Therapeutics, Inc.、Glenmark Pharmaceuticals、HBT Labs, Inc、Hoffmann-La Roche AG、InventisBio、Novartis AG、Radius Health、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、Zenopharm LLC.、Zentalis Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

SERD（選択エストロゲン受容体分解）薬市場は、種類と用途によって区分されます。世界のSERD（選択エストロゲン受容体分解）薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他

【用途別セグメント】
一次治療、二次治療

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- SERD（選択エストロゲン受容体分解）薬製品概要
- 種類別市場（RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他）
- 用途別市場（一次治療、二次治療）
- 調査の目的
・エグゼクティブサマリー
- 世界のSERD（選択エストロゲン受容体分解）薬販売量予測2017-2028
- 世界のSERD（選択エストロゲン受容体分解）薬売上予測2017-2028
- SERD（選択エストロゲン受容体分解）薬の地域別販売量
- SERD（選択エストロゲン受容体分解）薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別SERD（選択エストロゲン受容体分解）薬販売量
- 主要メーカー別SERD（選択エストロゲン受容体分解）薬売上
- 主要メーカー別SERD（選択エストロゲン受容体分解）薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他）
- SERD（選択エストロゲン受容体分解）薬の種類別販売量
- SERD（選択エストロゲン受容体分解）薬の種類別売上
- SERD（選択エストロゲン受容体分解）薬の種類別価格
・用途別市場規模（一次治療、二次治療）
- SERD（選択エストロゲン受容体分解）薬の用途別販売量
- SERD（選択エストロゲン受容体分解）薬の用途別売上
- SERD（選択エストロゲン受容体分解）薬の用途別価格
・北米市場
- 北米のSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（トルコ、サウジアラビア）
・企業情報
Amneal Pharmaceuticals Inc、AstraZeneca, Plc.、Dr. Reddy's Laboratories、Eli Lilly and Company、G1 Therapeutics, Inc.、Glenmark Pharmaceuticals、HBT Labs, Inc、Hoffmann-La Roche AG、InventisBio、Novartis AG、Radius Health、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、Zenopharm LLC.、Zentalis Pharmaceuticals
・産業チェーン及び販売チャネル分析
- SERD（選択エストロゲン受容体分解）薬の産業チェーン分析
- SERD（選択エストロゲン受容体分解）薬の原材料
- SERD（選択エストロゲン受容体分解）薬の生産プロセス
- SERD（選択エストロゲン受容体分解）薬の販売及びマーケティング
- SERD（選択エストロゲン受容体分解）薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- SERD（選択エストロゲン受容体分解）薬の産業動向
- SERD（選択エストロゲン受容体分解）薬のマーケットドライバー
- SERD（選択エストロゲン受容体分解）薬の課題
- SERD（選択エストロゲン受容体分解）薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global SERD (Selective Estrogen Receptor Degrader) Drugs Market
The global SERD (Selective Estrogen Receptor Degrader) Drugs market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, RAD1901 accounting for % of the SERD (Selective Estrogen Receptor Degrader) Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While First-Line Treatment segment is altered to an % CAGR throughout this forecast period.
China SERD (Selective Estrogen Receptor Degrader) Drugs market size is valued at US$ million in 2021, while the North America and Europe SERD (Selective Estrogen Receptor Degrader) Drugs are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe SERD (Selective Estrogen Receptor Degrader) Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global SERD (Selective Estrogen Receptor Degrader) Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global SERD (Selective Estrogen Receptor Degrader) Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global SERD (Selective Estrogen Receptor Degrader) Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global SERD (Selective Estrogen Receptor Degrader) Drugs market.
Global SERD (Selective Estrogen Receptor Degrader) Drugs Scope and Market Size
SERD (Selective Estrogen Receptor Degrader) Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global SERD (Selective Estrogen Receptor Degrader) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
RAD1901
GDC-9545
AZD9833
SAR439859
Faslodex
Others
Segment by Application
First-Line Treatment
Second-Line Treatment
By Company
Amneal Pharmaceuticals Inc
AstraZeneca, Plc.
Dr. Reddy’s Laboratories
Eli Lilly and Company
G1 Therapeutics, Inc.
Glenmark Pharmaceuticals
HBT Labs, Inc
Hoffmann-La Roche AG
InventisBio
Novartis AG
Radius Health
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zenopharm LLC.
Zentalis Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 RAD1901
1.2.3 GDC-9545
1.2.4 AZD9833
1.2.5 SAR439859
1.2.6 Faslodex
1.2.7 Others
1.3 Market by Application
1.3.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 First-Line Treatment
1.3.3 Second-Line Treatment
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Perspective (2017-2028)
2.2 SERD (Selective Estrogen Receptor Degrader) Drugs Growth Trends by Region
2.2.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Region (2017-2022)
2.2.3 SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Region (2023-2028)
2.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Dynamics
2.3.1 SERD (Selective Estrogen Receptor Degrader) Drugs Industry Trends
2.3.2 SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
2.3.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Challenges
2.3.4 SERD (Selective Estrogen Receptor Degrader) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Revenue
3.1.1 Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Revenue (2017-2022)
3.1.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Players (2017-2022)
3.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue
3.4 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Concentration Ratio
3.4.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in 2021
3.5 SERD (Selective Estrogen Receptor Degrader) Drugs Key Players Head office and Area Served
3.6 Key Players SERD (Selective Estrogen Receptor Degrader) Drugs Product Solution and Service
3.7 Date of Enter into SERD (Selective Estrogen Receptor Degrader) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 SERD (Selective Estrogen Receptor Degrader) Drugs Breakdown Data by Type
4.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Type (2017-2022)
4.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Type (2023-2028)
5 SERD (Selective Estrogen Receptor Degrader) Drugs Breakdown Data by Application
5.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Application (2017-2022)
5.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
6.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
6.2.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
6.2.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
6.2.3 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
6.3 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
6.3.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
6.3.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
6.3.3 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
6.4 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country
6.4.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022)
6.4.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
7.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
7.2.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
7.2.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
7.2.3 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
7.3 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
7.3.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
7.3.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
7.3.3 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
7.4 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country
7.4.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022)
7.4.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
8.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
8.2.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
8.3.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region
8.4.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
9.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
9.2.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
9.2.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
9.2.3 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
9.3 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
9.3.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
9.3.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
9.3.3 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
9.4 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country
9.4.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022)
9.4.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
10.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
10.2.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
10.3.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country
10.4.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amneal Pharmaceuticals Inc
11.1.1 Amneal Pharmaceuticals Inc Company Details
11.1.2 Amneal Pharmaceuticals Inc Business Overview
11.1.3 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.1.4 Amneal Pharmaceuticals Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.1.5 Amneal Pharmaceuticals Inc Recent Developments
11.2 AstraZeneca, Plc.
11.2.1 AstraZeneca, Plc. Company Details
11.2.2 AstraZeneca, Plc. Business Overview
11.2.3 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.2.4 AstraZeneca, Plc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.2.5 AstraZeneca, Plc. Recent Developments
11.3 Dr. Reddy’s Laboratories
11.3.1 Dr. Reddy’s Laboratories Company Details
11.3.2 Dr. Reddy’s Laboratories Business Overview
11.3.3 Dr. Reddy’s Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.3.4 Dr. Reddy’s Laboratories Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.3.5 Dr. Reddy’s Laboratories Recent Developments
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Details
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.4.4 Eli Lilly and Company Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.4.5 Eli Lilly and Company Recent Developments
11.5 G1 Therapeutics, Inc.
11.5.1 G1 Therapeutics, Inc. Company Details
11.5.2 G1 Therapeutics, Inc. Business Overview
11.5.3 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.5.4 G1 Therapeutics, Inc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.5.5 G1 Therapeutics, Inc. Recent Developments
11.6 Glenmark Pharmaceuticals
11.6.1 Glenmark Pharmaceuticals Company Details
11.6.2 Glenmark Pharmaceuticals Business Overview
11.6.3 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.6.4 Glenmark Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.6.5 Glenmark Pharmaceuticals Recent Developments
11.7 HBT Labs, Inc
11.7.1 HBT Labs, Inc Company Details
11.7.2 HBT Labs, Inc Business Overview
11.7.3 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.7.4 HBT Labs, Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.7.5 HBT Labs, Inc Recent Developments
11.8 Hoffmann-La Roche AG
11.8.1 Hoffmann-La Roche AG Company Details
11.8.2 Hoffmann-La Roche AG Business Overview
11.8.3 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.8.4 Hoffmann-La Roche AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.8.5 Hoffmann-La Roche AG Recent Developments
11.9 InventisBio
11.9.1 InventisBio Company Details
11.9.2 InventisBio Business Overview
11.9.3 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.9.4 InventisBio Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.9.5 InventisBio Recent Developments
11.10 Novartis AG
11.10.1 Novartis AG Company Details
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.10.4 Novartis AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.10.5 Novartis AG Recent Developments
11.11 Radius Health
11.11.1 Radius Health Company Details
11.11.2 Radius Health Business Overview
11.11.3 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.11.4 Radius Health Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.11.5 Radius Health Recent Developments
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Company Details
11.12.2 Sanofi S.A. Business Overview
11.12.3 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.12.4 Sanofi S.A. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.12.5 Sanofi S.A. Recent Developments
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Teva Pharmaceutical Industries Ltd. Company Details
11.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.13.3 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.13.4 Teva Pharmaceutical Industries Ltd. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.14 Zenopharm LLC.
11.14.1 Zenopharm LLC. Company Details
11.14.2 Zenopharm LLC. Business Overview
11.14.3 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.14.4 Zenopharm LLC. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.14.5 Zenopharm LLC. Recent Developments
11.15 Zentalis Pharmaceuticals
11.15.1 Zentalis Pharmaceuticals Company Details
11.15.2 Zentalis Pharmaceuticals Business Overview
11.15.3 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.15.4 Zentalis Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.15.5 Zentalis Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のSERD（選択エストロゲン受容体分解）薬市場インサイト及び予測（RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他）(Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界のSERD（選択エストロゲン受容体分解）薬市場インサイト及び予測（RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp